Draper Awarded $3 Million from ARPA-Hs Sprint for Womens Health to Advance the Well-being of Pregnant Women by Leveraging its Innovative Organ-on-chip Capabilities
Summary
The goal of Drapers program is to address the challenge of drug safety during pregnancy without needing to test on pregnant women. The Draper team, led by Principal Investigators Dr. Corin Williams and Dr. Hesham Azizgolshani, will use the ARPA-H award to develop a bioengineered model of human pregnancy. Drapers advanced capabilities in microphysiological systems will allow testing of pregnancy-relevant medications in dozens of miniature human pregnancy models at a time and determine if they are safe. "Healthy pregnancies affect all human life, so we believe that many people will care about the outcome of our program," said Corin Williams, Biomedical Engineer and Principal Investigator. Multidisciplinary teams drawn from a broad and deep talent pool of 1,600 engineers and scientists collaborate to develop first-of-a-kind solutions.